Compare Stocks: CUE, RIGL, SANA, and CADL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.88 -2.8%	$11.47	$4.35 ▼ $14.00	$832.54M	-0.48	1.48 million shs	962,034 shs
CUE Cue Biopharma	$25.51 -7.1%	$29.26	$4.97 ▼ $45.50	$185.20M	2.45	361,148 shs	283,767 shs
RIGL Rigel Pharmaceuticals	$48.89 -1.0%	$43.91	$24.95 ▼ $52.24	$904.47M	1.2	358,365 shs	182,245 shs
SANA Sana Biotechnology	$2.91 -0.7%	$3.46	$2.61 ▼ $6.55	$871.14M	2.12	3.19 million shs	3.04 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+1.54%	-0.18%	-14.38%	+8.64%	+101.99%
CUE Cue Biopharma	-12.61%	-2.90%	-1.54%	-13.02%	-95.70%
RIGL Rigel Pharmaceuticals	+2.45%	+4.82%	+6.20%	+26.18%	+72.41%
SANA Sana Biotechnology	-0.34%	-5.48%	-25.45%	-16.05%	-12.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.88 -2.8%	$11.47	$4.35 ▼ $14.00	$832.54M	-0.48	1.48 million shs	962,034 shs
CUE Cue Biopharma	$25.51 -7.1%	$29.26	$4.97 ▼ $45.50	$185.20M	2.45	361,148 shs	283,767 shs
RIGL Rigel Pharmaceuticals	$48.89 -1.0%	$43.91	$24.95 ▼ $52.24	$904.47M	1.2	358,365 shs	182,245 shs
SANA Sana Biotechnology	$2.91 -0.7%	$3.46	$2.61 ▼ $6.55	$871.14M	2.12	3.19 million shs	3.04 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+1.54%	-0.18%	-14.38%	+8.64%	+101.99%
CUE Cue Biopharma	-12.61%	-2.90%	-1.54%	-13.02%	-95.70%
RIGL Rigel Pharmaceuticals	+2.45%	+4.82%	+6.20%	+26.18%	+72.41%
SANA Sana Biotechnology	-0.34%	-5.48%	-25.45%	-16.05%	-12.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.73	Moderate Buy	$20.14	85.14% Upside
CUE Cue Biopharma	2.33	Hold	$83.00	225.36% Upside
RIGL Rigel Pharmaceuticals	2.57	Moderate Buy	$59.00	20.68% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	220.73% Upside

Current Analyst Ratings Breakdown

Latest CUE, RIGL, SANA, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$12.00 ➝ $18.00
9/21/2026	CUE Cue Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/18/2026	CUE Cue Biopharma	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$83.00
9/18/2026	CUE Cue Biopharma	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$83.00
9/17/2026	CUE Cue Biopharma	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/9/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/27/2026	CUE Cue Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	CADL Candel Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	RIGL Rigel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$40.00 ➝ $49.00

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
CUE Cue Biopharma	$27.47M	6.74	N/A	N/A	$10.08 per share	2.53
RIGL Rigel Pharmaceuticals	$294.28M	3.07	$6.84 per share	7.15	$21.57 per share	2.27
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$38.18M	-$1.41	N/A	N/A	N/A	N/A	-76.98%	-48.50%	11/12/2026 (Estimated)
CUE Cue Biopharma	-$26.60M	-$27.02	N/A	N/A	N/A	-435.83%	-620.06%	-291.15%	11/11/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	3.00	11.32	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)

Latest CUE, RIGL, SANA, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CUE Cue Biopharma	-$1.69	-$24.14	-$22.45	-$24.14	$3.00 million	$7.88 million
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.38	16.09	16.09
CUE Cue Biopharma	N/A	1.25	1.25
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79
SANA Sana Biotechnology	N/A	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
CUE Cue Biopharma	35.04%
RIGL Rigel Pharmaceuticals	66.23%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
CUE Cue Biopharma	14.56%
RIGL Rigel Pharmaceuticals	10.47%
SANA Sana Biotechnology	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	55	76.52 million	65.58 million	Optionable
CUE Cue Biopharma	29	7.26 million	6.21 million	Optionable
RIGL Rigel Pharmaceuticals	174	18.50 million	16.57 million	Optionable
SANA Sana Biotechnology	142	299.36 million	223.32 million	Optionable

CUE, RIGL, SANA, and CADL Headlines

Recent News About These Companies

Bank of America Corp DE Purchases New Holdings in Sana Biotechnology, Inc. $SANA

September 25, 2026 | marketbeat.com

6 'moonshot' biotech stocks that offer big risks, bigger rewards

September 23, 2026 | msn.com

Sana Biotechnology (NASDAQ:SANA) Shares Down 7.2% - Should You Sell?

September 23, 2026 | marketbeat.com

Sana Biotechnology (SANA)

September 23, 2026 | es.investing.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by Brokerages

September 20, 2026 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 10.4% - Still a Buy?

September 17, 2026 | marketbeat.com

Sana Biotechnology, Inc. (SANA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

September 15, 2026 | seekingalpha.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Brokerages

September 15, 2026 | marketbeat.com

Sana Biotechnology op Morgan Stanley conferentie: focus op diabetes

September 15, 2026 | nl.investing.com

Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Sana Biotechnology出席富国银行医疗健康大会：两大核心项目即将进入临床阶段

September 10, 2026 | cn.investing.com

Sana Biotechnology出席花旗2026年生物医药返校峰会：押注糖尿病疗法

September 10, 2026 | cn.investing.com

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 10, 2026 | seekingalpha.com

Bank of New York Mellon Corp Invests $1.67 Million in Sana Biotechnology, Inc. $SANA

September 9, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 7.9% - What's Next?

September 8, 2026 | marketbeat.com

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

September 7, 2026 | prnewswire.com

Corient Private Wealth LP Invests $2.19 Million in Sana Biotechnology, Inc. $SANA

September 3, 2026 | marketbeat.com

Sana Biotechnology to Present at September 2026 Investor Conferences

September 1, 2026 | globenewswire.com

16,675,173 Shares in Sana Biotechnology, Inc. $SANA Acquired by BlackRock Inc.

September 1, 2026 | marketbeat.com

As U.S.-China biotech race heats up, Seattle makes its case to D.C.

August 27, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, RIGL, SANA, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

$10.88 -0.31 (-2.77%)

Closing price 04:00 PM Eastern

Extended Trading

$10.80 -0.09 (-0.78%)

As of 05:16 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Cue Biopharma NASDAQ:CUE

$25.51 -1.94 (-7.07%)

Closing price 04:00 PM Eastern

Extended Trading

$25.07 -0.44 (-1.74%)

As of 05:09 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Rigel Pharmaceuticals NASDAQ:RIGL

$48.89 -0.47 (-0.95%)

Closing price 04:00 PM Eastern

Extended Trading

$48.88 -0.02 (-0.03%)

As of 04:20 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Sana Biotechnology NASDAQ:SANA

$2.91 -0.02 (-0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$2.97 +0.06 (+2.06%)

As of 05:14 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUE, RIGL, SANA, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUE, RIGL, SANA, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUE, RIGL, SANA, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, RIGL, SANA, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

Cue Biopharma NASDAQ:CUE

Rigel Pharmaceuticals NASDAQ:RIGL

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUE, RIGL, SANA, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUE, RIGL, SANA, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUE, RIGL, SANA, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, RIGL, SANA, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

Cue Biopharma NASDAQ:CUE

Rigel Pharmaceuticals NASDAQ:RIGL

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools